Radiotherapy Induced Oral Mucositis Treatment Global Market Report 2025

The radiotherapy induced oral mucositis treatment market size has grown strongly in recent years. It will grow from $1.76 billion in 2024 to $1.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to the rising global incidence of cancer, increased awareness of oral mucositis, a higher prevalence of head and neck cancers, the expansion of healthcare infrastructure, and a growing demand for supportive care solutions.

The radiotherapy induced oral mucositis treatment market size is expected to see strong growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period is expected to be driven by the increasing adoption of regenerative medicine approaches, the rising incidence of radiotherapy, a higher prevalence of chronic diseases, the expansion of telehealth services, and a growing demand for home-based care solutions. Key trends during this period include advancements in intensity-modulated radiotherapy techniques, the development of targeted therapies, integration of telemedicine, personalized medicine approaches, and improvements in imaging techniques.

The rising global prevalence of cancer is expected to drive the growth of the radiotherapy-induced oral mucositis treatment market. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and organs. This condition arises from genetic mutations influenced by environmental and lifestyle factors. The increasing global prevalence of cancer is largely attributed to factors such as an aging population, lifestyle choices such as tobacco use, obesity, and alcohol consumption, as well as environmental influences such as air pollution. Radiotherapy-induced oral mucositis treatment helps cancer patients manage the painful side effects of mucosal damage caused by radiotherapy, allowing them to better tolerate treatment and maintain proper nutritional intake, which ultimately improves their quality of life during cancer care. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization, reported that more than 3 million people in the UK were living with cancer in 2024, and this number is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising global prevalence of cancer is driving the growth of the radiotherapy-induced oral mucositis treatment market.

Leading companies in the radiotherapy-induced oral mucositis treatment market are focusing on developing innovative products, such as low-level laser therapy, to accelerate healing, reduce pain, and improve patient outcomes during cancer treatment. Low-level laser therapy, also known as cold laser therapy or photobiomodulation, is a non-invasive treatment that uses low-power lasers or light-emitting diodes (LEDs) to stimulate healing and reduce pain and inflammation. For example, in October 2024, Jaguar Health Inc., a US-based pharmaceutical company, launched Gelclair, an oral mucositis prescription gel. Specifically designed to manage the pain associated with oral mucositis, a condition that affects up to 90% of head and neck cancer patients undergoing chemotherapy and radiotherapy, Gelclair adheres to the mucosal surface of the mouth, providing rapid and long-lasting pain relief without the stinging or numbing effects typically associated with other treatments.

In September 2024, InfuSystem Holdings Inc., a US-based healthcare services company, partnered with ChemoMouthpiece LLC. This partnership enables InfuSystem to exclusively distribute the Chemo Mouthpiece in the United States, aiming to reduce the incidence and severity of oral mucositis in cancer patients undergoing chemotherapy and radiotherapy. ChemoMouthpiece LLC is a US-based company offering a treatment for radiotherapy-induced oral mucositis.

Major players in the radiotherapy induced oral mucositis treatment market are Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Ltd., Almirall S.A., Fagron Group BV, Sage Products LLC, Soligenix Inc., EUSA Pharma Ltd., Galera Therapeutics Inc., Enzychem Lifesciences Corp., Jaguar Health Inc., EpicentRx Inc., MONOPAR Therapeutics Inc., Solasia Pharma KK, Cellceutix Corporation, Innovation Pharmaceuticals Inc.

North America was the largest region in the radiotherapy induced oral mucositis treatment market in 2024. The regions covered in radiotherapy induced oral mucositis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the radiotherapy induced oral mucositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Radiotherapy-induced oral mucositis treatment involves medical interventions aimed at managing and alleviating the painful condition of oral mucositis caused by radiotherapy. These treatments focus on reducing inflammation, preventing infection, relieving pain, and promoting healing of the mucosal tissues in the mouth, which are damaged during cancer treatments, especially in patients receiving radiotherapy for head and neck cancers.

The primary drug classes used in treating radiotherapy-induced oral mucositis include antibiotics, antifungals, anti-inflammatory agents, and anti-neoplastic drugs. Antibiotics help prevent or treat bacterial infections by either killing the bacteria or inhibiting their growth. Treatment options include topical agents, systemic medications, and medical devices. Radiotherapy techniques used in treatment include external beam radiation therapy (EBRT), intensity-modulated radiation therapy (IMRT), brachytherapy, proton therapy, stereotactic radiosurgery (SRS), and others. The severity of oral mucositis is categorized as mild, moderate, or severe. This treatment is typically administered in hospitals, oncology centers, research institutes, and dental clinics.

The radiotherapy induced oral mucositis treatment market research report is one of a series of new reports that provides radiotherapy induced oral mucositis treatment market statistics, including the radiotherapy induced oral mucositis treatment industry's global market size, regional shares, competitors with a radiotherapy induced oral mucositis treatment market share, detailed radiotherapy induced oral mucositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy induced oral mucositis treatment industry. This radiotherapy induced oral mucositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radiotherapy-induced oral mucositis treatment market includes revenues earned by entities by providing services such as symptom management, cryotherapy, wound care and healing support, and pharmacological interventions and related products, including mouthwashes and rinses, topical gels and creams, oral sprays, and hydrogels and hydrating agents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.